Case Study: Dose-response modeling informs Phase 2 ulcerative colitis study design

Posted by Cytel

Nov 18, 2016 10:04:00 AM

 0bbd4624-95bf-4ce4-885f-642c983110de.png

Challenge

Our client had the following key questions which they wanted our pharmacometrics group to address for an upcoming phase 2 trial of their ulcerative colitis compound .

1) Can knowledge from pre-clinical and Phase 1 data inform on the optimal range of doses for an upcoming Phase 2 dose-ranging study?

2) How may the dose response observed in PD markers in Phase 1 healthy volunteers translate to the patient population?


The Cytel Solution:

Cytel pharmacometricians devised a modeling approach incorporating these elements :

  • Model Exposure-Response using PK and PD endpoints in healthy mice.
  • Modify model parameters for diseased mice and identify differences in response using both qualitative and quantitative measures.
  • Model the Exposure (Dose)-Response in the Phase 1 healthy volunteers.
  • Leverage all three models to create a predictive model for colitis patient PD responses.

Value Added

  • Predictions made by the modeling analyses were used to guide doses and assessments to be conducted in the Phase 2 study.

To find out more about our pharmacometrics expertise click below.

Pharmacometrics 

Related reading:

It's time to bridge the gap between pharmacometrics and biostatistics

Case Study: Exposure response modeling in hematology

An efficient tool for model- based meta--analysis 

Topics: biostatistics, Cytel Strategic Consulting, pharmacometrics, PK/PD, Case Study

The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.

 

Posts by Topic

see all

Recent Posts